Aimee Mishkin

As Head of Regulatory Affairs, Aimee is responsible for oversight and management of the Regulatory Affairs function at Kymera, including nonclinical, CMC and clinical regulatory strategies for all Kymera development candidates. Aimee has over 15 years of regulatory affairs experience in the biotechnology industry, serving as the lead regulatory strategist for several commercially successful medicines. Before joining Kymera, Aimee gained significant experience in small and midsized companies, with increasing levels of responsibility and leadership roles through her tenure at Forma Therapeutics, Clovis Oncology, Array BioPharma and OSI Pharmaceuticals. She has supported early and late-stage drug development programs in multiple therapeutic areas and has extensive experience in biotech-pharma co-development partnerships, regulatory intelligence research and due diligence, as well as clinical development plan execution. Aimee is a passionate patient advocate in her personal and professional lives with a focus on oncology patient engagement and advocacy and patient-focused drug development. She holds a B.S. in Molecular, Cell and Developmental Biology and a B.A in English Literature from the University of Colorado, and an M.S. in Pharmacology and Toxicology from Michigan State University.

Aimee also serves as the Program Team Leader of Kymera’s IRAKiMID program, KT-413, currently under development for MYD88-mutant Diffuse large B-cell lymphoma, or DLBCL.